The British journal of radiology · 2026
Impact of PSMA PET/CT on initial staging and planning of definitive radiation therapy in prostate cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elsaka Rasha, Hegazy Hanady, Eldrieny Ahmed, Kotb Mahmoud, Morsi Mohamed, Elsaid Amr
Аннотация
OBJECTIVES: Comparing risk grouping, target delineation, and dosimetric parameters between RT plans based on conventional imaging (CT and/or MRI pelvis with bone scan) versus 18F-PSMA PET/CT in the same patients.
METHODS: A 75 newly diagnosed PCa patients treated with definitive RT between January 2019 and December 2022 at our center were included. Each underwent standard imaging and 18F-PSMA PET/CT. Two RT plans were generated; one from conventional imaging and another from PSMA PET/CT data using IMRT or RapidArc on the Eclipse (Varian, USA) system. Plans were compared regarding target volumes (TVs), dose-volume histograms (DVH), and doses to organs at risk (OARs).
RESULTS: Mean age was 69.6 ± 8.1 years, and mean pretreatment PSA was 33.47 ± 42.05 ng/mL. Gleason score (GS) was 7 in 50.7% and 8-10 in 26.6%. PSMA-PET/CT altered TVs in 26 patients (34.7%). PSMA-based RT plans showed significantly higher rectal V60% (19.96% vs 18.1%, P = .024), femoral maximum dose (46.37 Gy vs 41.98 Gy, P = .006), and bowel maximum dose (54.7 Gy vs 46.3 Gy, P = .014). Upstaged patients had larger mean prostate volumes (77.53 ± 34.76 cc vs 59.76 ± 30.6 cc; P = .026).
CONCLUSION: 18F-PSMA-PET/CT significantly impacts staging and RT planning in prostate cancer, leading to altered TVs and dosimetry, significantly in patients with larger prostates, but non significantly in patients with GS ≥ 8, and higher PSA levels.
ADVANCES IN KNOWLEDGE: PSMA PET/CT meaningfully changes staging, TVs, and dosimetry. It highlights the modality's value in improving accuracy in definitive RT planning.
METHODS: A 75 newly diagnosed PCa patients treated with definitive RT between January 2019 and December 2022 at our center were included. Each underwent standard imaging and 18F-PSMA PET/CT. Two RT plans were generated; one from conventional imaging and another from PSMA PET/CT data using IMRT or RapidArc on the Eclipse (Varian, USA) system. Plans were compared regarding target volumes (TVs), dose-volume histograms (DVH), and doses to organs at risk (OARs).
RESULTS: Mean age was 69.6 ± 8.1 years, and mean pretreatment PSA was 33.47 ± 42.05 ng/mL. Gleason score (GS) was 7 in 50.7% and 8-10 in 26.6%. PSMA-PET/CT altered TVs in 26 patients (34.7%). PSMA-based RT plans showed significantly higher rectal V60% (19.96% vs 18.1%, P = .024), femoral maximum dose (46.37 Gy vs 41.98 Gy, P = .006), and bowel maximum dose (54.7 Gy vs 46.3 Gy, P = .014). Upstaged patients had larger mean prostate volumes (77.53 ± 34.76 cc vs 59.76 ± 30.6 cc; P = .026).
CONCLUSION: 18F-PSMA-PET/CT significantly impacts staging and RT planning in prostate cancer, leading to altered TVs and dosimetry, significantly in patients with larger prostates, but non significantly in patients with GS ≥ 8, and higher PSA levels.
ADVANCES IN KNOWLEDGE: PSMA PET/CT meaningfully changes staging, TVs, and dosimetry. It highlights the modality's value in improving accuracy in definitive RT planning.